Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06041555Recruiting
MRI-guided radiotherapy study for five cancer types
This study collects MRI scans and treatment data from patients getting MRI-guided radiotherapy for certain cancers. It aims to improve radiation treatment planning using imaging and biological information.
LyonAges 18 years+ - NCT05832086RecruitingPhase 2
Fasting-mimicking diet to improve prostate cancer and metabolism
This trial tests whether an intermittent, fasting-like diet can help control metastatic prostate cancer and improve metabolic health in men on hormone therapy. Participants follow a specific diet plan and are monitored by the study team.
Duarte, CaliforniaAges Any age - NCT04545957Recruiting
Radiation planning study using MRI for adults with cancer
This trial tests a “master protocol” approach to use MRI (a detailed body scan) to help plan radiation treatment for people with cancer. It may help doctors customize radiation more accurately, depending on your specific cancer type.
Boston, MassachusettsAges 18 years+ - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06748456Recruiting
PSA test use in general practice
This trial tests a program to help doctors use PSA tests based on evidence. It looks at whether a cluster meeting can improve how PSA tests are used in general practice.
CopenhagenAges Any age - NCT06895291Recruiting
Whole body MRI for cancer patients
This study uses whole-body MRI scans to see if they help monitor or diagnose cancer better. It may be an option if your doctor has already recommended this type of scan.
Bologna, BOAges 18 years+ - NCT02526797Enrolling by invitation
MRI scan study for men on active surveillance
This trial tests how a special MRI scan (with multiple measurements) may help men with low-risk prostate cancer who are monitoring it closely instead of treating right away. It may help doctors better understand the cancer’s status during active surveillance.
HerlevAges 18–75 - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT04797039Recruiting
MRI-guided freezing treatment for localized prostate cancer
This trial studies a treatment where doctors use MRI pictures to guide freezing of a prostate tumor. It may help men with smaller, well-placed prostate cancers who cannot or do not want surgery or radiation right now.
Rochester, MinnesotaAges 30–100 - NCT05792722Recruiting
Testing a prostate-sparing bladder surgery for bladder cancer
This trial studies whether a “prostate-sparing” radical cystectomy is safe and effective for bladder cancer patients who are having surgery. It aims to see if this approach can treat bladder cancer while reducing prostate-related side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06818682RecruitingPhase 2
Shortened hormone therapy with radiation for high-risk prostate cancer
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
Mumbai, MaharashtraAges 19–99 - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT07369570Recruiting
Watching low-risk prostate lesions with repeat MRI scans
This trial uses repeated MRI scans to monitor prostate lesions that have a low chance of being aggressive cancer. It is for people who have suspicious spots but whose initial biopsies did not find high-grade cancer.
KuopioAges 40 years+ - NCT03648359Enrolling by invitation
MRI scans to monitor low-risk prostate cancer in active surveillance
This trial uses special MRI scans to help track low-risk prostate cancer while you stay on active surveillance (meaning no immediate treatment). It may help your care team better understand changes in the cancer over time.
HerlevAges 18–75 - NCT04175431RecruitingPhase 2
PSMA or FACBC PET scan guided treatment for prostate cancer recurrence
This Phase 2 study tests using a special PET/CT scan (PSMA or FACBC) to guide treatment for prostate cancer that has come back after surgery and radiation. The goal is to see whether this scan-based approach can better target cancer in the prostate area (and help plan the right treatment).
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06717711RecruitingPhase 3
Shockwave therapy for penis recovery after prostate cancer surgery
This trial tests if low-intensity shockwaves can help men regain erectile function after robot-assisted prostate surgery. If you had nerve-sparing surgery and have good erections before treatment, this may help you recover faster.
Rome, RMAges 18–75 - NCT05155046RecruitingPhase 2
Scan to check prostate cancer response after focused radiation
This study tests whether a special PET scan tracer (18F-DCFPyL) can show how well focused radiation (SBRT) is working for localized prostate cancer. It may help doctors spot treatment response earlier and tailor follow-up care.
Bethesda, MarylandAges 18–120 - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
La Jolla, CaliforniaAges 18 years+
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,215 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.